United States: Commentary: Federal Circuit Delays Launch Of First U.S. Biosimilar

Last Updated: September 17 2015
Article by Mark E. Nickas

Originally published in the Daily Record

On July 21 the U.S. Court of Appeals for the Federal Circuit issued an opinion interpreting key provisions of the Biologics Price Competition and Innovation Act of 2009 in Amgen, Inc. v. Sandoz, Inc.

The BPCIA allows the Food and Drug Administration to approve new biological drugs, or biologics, that function identically to previously-licensed biologics. The BPCIA creates an abbreviated approval pathway that enables an applicant for a so-called "biosimilar" to rely on much of the clinical data used during approval of the drug that the biosimilar is intended to imitate, i.e., the reference biologic.

On March 6, the FDA granted the first biosimilar license in the U.S. to Sandoz's Zarxio, which is biosimilar to Amgen's Neupogen. Due to the Federal Circuit's decision in Amgen, however, Sandoz will not be able to launch Zarxio until September.

A primary objective of the BPCIA is to lower the cost of biologics by encouraging the development of biosimilars to compete with existing biologics in the relevant markets. The BPCIA is modeled on the Drug Price Competition and Patent Term Restoration Act of 1984, commonly called the "Hatch-Waxman Act," which has been highly successful at creating a market for generic competition to chemical drugs, i.e., synthetically-derived compounds, often called "small-molecule" drugs.

The Hatch-Waxman Act provides an expedited mechanism for FDA approval of new small-molecule drugs that are structurally identical to previously-licensed drugs. The BPCIA seeks to emulate the success of the Hatch-Waxman Act while addressing the unique issues that arise in the approval process for biologics, which are inherently more complex than small-molecule drugs.

An important difference between the Hatch-Waxman Act and the BPCIA pertains to the requirements for disclosure of patents that protect approved drugs. Under the Hatch-Waxman Act, the sponsor of an approved drug must disclose all patents that cover the drug's structure and method of use. The patents, along with other information about the drug, are listed in a public compendium commonly called the "Orange Book."

Care to dance?

An applicant for approval of a generic small-molecule drug must certify that marketing of its product would not create liability for infringing any of the listed patents that protect the approved, brand-name version. In contrast, the approval pathway for novel biologics does not require sponsors to disclose patents related to their products. Consequently, the BPCIA establishes a mechanism in which patent information is exchanged privately between a biosimilar applicant and the reference product sponsor, or RPS. This novel and complex process, sometimes called the "patent dance," was at the core of the dispute in Amgen.

The first BPCIA-related issue in Amgen was whether a biosimilar applicant is required to participate in the patent dance. According to the BPCIA, a biosimilar applicant "shall provide to the reference product sponsor a copy of the application" within 20 days of receiving notice that the FDA has accepted the application for review.

Sandoz was informed that its Zarxio application, which referenced Neupogen, had been accepted for review on July 7, 2014. The following day, Sandoz notified Amgen of the filing but did not provide a copy of the application. When Amgen requested a copy, Sandoz responded that it had "opted not to provide" the application within the statutory time frame.

A separate provision of the BPCIA states that a biosimilar applicant that fails to provide the application to the RPS constructively infringes any patent that claims the biologic or its use. Consequently, Amgen sued Sandoz in October 2014 for patent infringement as well as unfair competition and conversion.

In a split decision, two members of the Federal Circuit's three-judge panel held that the BPCIA does not require Sandoz to engage in the patent dance. Writing for the majority, Judge Alan D. Lourie noted that the subsection of the statute containing the relevant provision uses the verb "shall," whereas the following subsection uses the verb "may." Lourie conceded that such a language distinction would support a reading that the "shall" provision is mandatory if the provision were taken in isolation. According to Lourie, however, this provision "cannot be read in isolation."

As indicated above, other sections of the statute allow the RPS to sue for patent infringement if the biosimilar applicant fails to disclose the application within the prescribed period. Thus, Lourie reasoned, the BPCIA contemplates that a biosimilar applicant might take such a course of action because the statute affords the RPS recourse for when it occurs. Consequently, compliance with the statutory provision to provide the biosimilar application to the RPS is optional, and Sandoz had the right not to share its application with Amgen.

Also contested in Amgen was the BPCIA's provision on notice of commercial marketing. Under the BPCIA, a biosimilar applicant "shall provide notice to the reference product sponsor not later than 180 days before the date of the first commercial marketing of the biological product licensed under subsection (k)."

The first issue related to this provision was whether notice could be provided before the biosimilar has received FDA approval. In its communication to Amgen on July 8, 2014, Sandoz indicated that it intended to market Zarxio immediately upon approval. When Zarxio was approved on March 6, Sandoz again notified Amgen of its intent to market the biosimilar. Sandoz argued, however, that it had fulfilled the statutory requirements with its July 2014 notice and was therefore entitled to begin marketing Zarxio in March.

On the only issue on which the panel was unanimous, the Federal Circuit held that Sandoz's July 2014 notice of commercial marketing was ineffective. According to the court, the BPCIA requires a biosimilar applicant to give notice to the RPS after the biosimilar has been approved. The court noted that the provision for notice of commercial marketing refers to "the biological product licensed under subsection (k)," whereas other provisions related to the patent dance describe "the biological product that is the subject of [the] application." The court also observed that products can change during the application process. Consequently, an RPS may not know which of its patents to assert until the biosimilar and its uses have been finalized.

A related issue was whether providing notice of commercial marketing is mandatory for a biosimilar applicant. The majority answered this question in the affirmative. Here Lourie found that the "shall provide" language of the provision was not countervailed by other provisions that specify the consequences of failing to do so.

In contrast to the provisions relating to the patent dance, the provisions on notice of commercial marketing provide no remedy to the RPS for the applicant's failure to disclose its plans. Thus, because the BPCIA does not contemplate noncompliance with this provision, it is obligatory. Adopting this interpretation, the court found that Sandoz had not fulfilled its notice obligations until its communication on March 6 and therefore could not market Zarxio until Sept. 2.

Perhaps the most surprising outcome of Amgen is its effect on patent-independent market exclusivity of biologics. The BPCIA forbids FDA approval of a biosimilar until 12 years after licensure of the reference biologic. Amgen effectively extends this period of market exclusivity by nearly six months. Nonetheless, given the complexity of the BPCIA and the divergent opinions of the Amgen panel members, it seems unlikely that we've heard the final word on this case.

Mark E. Nickas is an associate at McLane, Graf, Raulerson & Middleton, where he specializes in patent prosecution and client counseling in the life sciences. He holds a doctorate in biology. A version of this column originally appeared in Massachusetts Lawyers Weekly, sister publication to The Daily Record.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.